TriangleNCT00022633 · OUTCOME
Progression-free Survival in Patients Aged 70 Years and Older
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 0-5 years
What was measured
Measured form date of registration to date of first observation of progression disease, death due to any cause, symptomatic deterioration, or early discontinuation of treatment.
Analysis population: Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.
Groups in this outcome
Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)
Patients received 1000 mg /m\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)
| Group | Source count |
|---|---|
| Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70) | 51 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70) | 6 | Not reported | 4 | 7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4
- upper Limit
- 7
- value
- 6
- denoms
- counts
- group Id
- OG000
- value
- 51
- units
- Participants
- description
- Measured form date of registration to date of first observation of progression disease, death due to any cause, symptomatic deterioration, or early discontinuation of treatment.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients received 1000 mg /m\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)
- id
- OG000
- title
- Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)
- param Type
- MEDIAN
- population Description
- Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.
- reporting Status
- POSTED
- time Frame
- 0-5 years
- title
- Progression-free Survival in Patients Aged 70 Years and Older
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice